Diagnostic, Prognostic, and Predictive IHC in Lung Neuroendocrine Neoplasia
October 21, 2026 | Webinar Recording
Watch the Webinar Recording
Register for access to this educational webinar recording.
Register & Watch WebinarSession Description
In this session, we will cover updates in immunohistochemistry (IHC) for lung neuroendocrine neoplasia, a field that has seen significant recent progress.
We will cover an update on diagnostic markers for lung carcinoids/NETs, including markers for site of origin (e.g., OTP), markers of emerging carcinoid/NET subtypes, as well as markers for various known and recently emerging mimickers of NETs that can present challenges in practice.
We will also cover diagnostic markers for neuroendocrine carcinomas, including POU2F3, and IHC for mimickers of NECs.
For prognostic markers, we will discuss the upcoming WHO update for lung carcinoid/NET grading, which will incorporate Ki67, and anticipated challenges.
Lastly, we will briefly discuss predictive markers, including DLL3.
Learning Objectives
Attendees will gain an updated understanding of the following applications of IHC in lung neuroendocrine neoplasia:
- Diagnosis
- Prognosis
- Theranosis
Target Audience
Pathologists, pathology residents and fellows, patient-facing clinicians, and scientists with an interest in neuroendocrine neoplasia.